MBX Biosciences, Inc. Common Stock vs CYATY
A head-to-head of MBX Biosciences, Inc. Common Stock (MBX) and CYATY (CYATY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | MBX | CYATY |
|---|---|---|
| Market Cap | $1.95B | $372.43B |
| P/E (TTM) | — | 31.75 |
| Forward P/E | 0.00 | 29.07 |
| P/S | 0.00 | 0.80 |
| P/B | 4.36 | 6.98 |
| EV/EBITDA | 0.00 | 16.60 |
| Dividend Yield | — | 0.00% |
| Profit Margin | 0.00% | 16.87% |
| Gross Margin | — | 25.62% |
| Operating Margin | 0.00% | 15.29% |
| Revenue Growth (YoY) | 0.00% | +52.45% |
| FCF Yield | -4.09% | 23.93% |
| Debt / Equity | 0.04 | 27.90 |
| Current Ratio | 30.79 | 1.60 |
Which is better: MBX Biosciences, Inc. Common Stock or CYATY?
- ✓Larger by market cap: CYATY
- ✓More profitable (net margin): CYATY
- ✓Faster revenue growth: CYATY
- ✓Higher free-cash-flow yield: CYATY
Across 7 available metrics, CYATY leads 4–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare MBX Biosciences, Inc. Common Stock with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.